title: Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.
abstract: Plasma levels of thrombin-antithrombin III complex (TAT), plasmin-alpha 2-plasmin inhibitor complex (PIC) and active plasminogen activator inhibitor (PAI) were assayed in 66 cases of disseminated intravascular coagulation (DIC). Significant elevation of both TAT and PIC was observed in all cases of DIC. Most elevated levels of TAT were seen in DIC with acute promyelocytic leukaemia (APL) and sepsis. The highest levels of PIC were seen in DIC with APL but were much lower in sepsis. A significant elevation in active PAI was observed in DIC due to acute leukaemia (apart from APL), chronic myeloid leukaemia and sepsis, but not in APL, non-Hodgkin lymphoma and cancer. Active PAI was higher in patients with multiple organ failure (MOF) than in those without MOF while PIC was lower in patients with this complication. Thus, the balance of coagulation and fibrinolysis varied according to the underlying cause of DIC; APL had more dominant activation of fibrinolysis, while sepsis had greater activation of coagulation. It is suggested that the inhibition of secondary fibrinolytic activation plays an important role in the progression of MOF by the disturbance of the microcirculation.
authors.affiliation: Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Asakura
authors.forename: H
authors.initials: H
authors.lastname: Jokaji
authors.forename: M
authors.initials: M
authors.lastname: Saito
authors.forename: C
authors.initials: C
authors.lastname: Uotani
authors.forename: I
authors.initials: I
authors.lastname: Kumabashiri
authors.forename: E
authors.initials: E
authors.lastname: Morishita
authors.forename: M
authors.initials: M
authors.lastname: Yamazaki
authors.forename: K
authors.initials: K
authors.lastname: Aoshima
authors.forename: T
authors.initials: T
authors.lastname: Matsuda
mesh_terms: D000933:Antifibrinolytic Agents / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation; D004211:Disseminated Intravascular Coagulation / Q000097:blood* / Q000150:complications; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000150:complications; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000150:complications; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000150:complications; D010447:Peptide Hydrolases / Q000378:metabolism; D015849:Plasminogen Inactivators / Q000378:metabolism; D018805:Sepsis / Q000097:blood / Q000150:complications; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D015849:Plasminogen Inactivators; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin